No Data
No Data
Towa Pharmaceutical, Nikkeikin HD, etc. (additional) Rating
Target Stock Price Change Code | Stock Name | Securities Company | Conventional | After Change |------|---------|---------|---------|<3288>|Open H | Yamato | 5800 yen | 5900 yen |<4553>|Towa Pharmaceuticals | Nomura | 2880 yen | 3000 yen |<4732>|USS |SMBC Nikko
Sony G, 24/3 operating profit down 7.2% to 1,208.8 billion yen, 25/3 forecast 5.5% increase to 1.275 trillion yen
The financial results for the fiscal year ending 2024/3 announced by Sony G <6758> were sales revenue of 13.20.768 billion yen, up 18.6% from the previous fiscal year, and operating profit of 1,208.8 billion yen, down 7.2% from the same period. As for the financial results for the fiscal year ending 2025/3, we plan that sales revenue will decrease 5.5% from the previous fiscal year to 12.31 trillion yen, and operating profit will increase 5.5% to 1.275 billion yen. It was announced that 1 share will be split into 5 shares using 9/30 as the reference date. Also, it is 2.46% of the number of issued shares (excluding treasury stock)
Towa Pharmaceutical Co FY Net Y16.17B Vs Net Y2.20B
Towa Pharmaceutical Co. Ltd. (4553.TO) Japan Year Ended March 31 GROUP 2024 2023 Revenue Y227.93 bln Y208.86 bln Operating Profit Y17.65 bln
TOWA Pharmaceutical: Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
TOWA Pharmaceutical: Financial Results Supplementary Explanatory Materials for the Fiscal Year Ending March 31, 2024
Convertible Stock List (Part 2) [Parabolic Signal Convertible Stock List]
○List of sales conversion stocks market code stock name closing price SAR Tokyo Stock Exchange Prime <1719> Ando Hazama 1154 1184 <1721> Comsys HD 3643 3796 <1885> Toa Kenshi 1041 1109 <1898> Century Tokyu 1755 1799 <1950> Nippon Densetsu 2065 222
No Data